BVNKF
Price
$27.50
Change
+$1.30 (+4.96%)
Updated
Jun 2 closing price
Capitalization
2.14B
CRMD
Price
$13.98
Change
+$0.80 (+6.07%)
Updated
Jun 6 closing price
Capitalization
893.93M
59 days until earnings call
Interact to see
Advertisement

BVNKF vs CRMD

Header iconBVNKF vs CRMD Comparison
Open Charts BVNKF vs CRMDBanner chart's image
Bavarian Nordic A/S
Price$27.50
Change+$1.30 (+4.96%)
Volume$508
Capitalization2.14B
CorMedix
Price$13.98
Change+$0.80 (+6.07%)
Volume$2.54M
Capitalization893.93M
BVNKF vs CRMD Comparison Chart
Loading...
CRMD
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
BVNKF vs. CRMD commentary
Jun 09, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is BVNKF is a Hold and CRMD is a StrongBuy.

Interact to see
Advertisement
COMPARISON
Comparison
Jun 09, 2025
Stock price -- (BVNKF: $26.80 vs. CRMD: $12.43)
Brand notoriety: BVNKF and CRMD are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: BVNKF: 229% vs. CRMD: 33%
Market capitalization -- BVNKF: $2.14B vs. CRMD: $893.93M
BVNKF [@Biotechnology] is valued at $2.14B. CRMD’s [@Biotechnology] market capitalization is $893.93M. The market cap for tickers in the [@Biotechnology] industry ranges from $323.27B to $0. The average market capitalization across the [@Biotechnology] industry is $2.25B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

BVNKF’s FA Score shows that 0 FA rating(s) are green whileCRMD’s FA Score has 0 green FA rating(s).

  • BVNKF’s FA Score: 0 green, 5 red.
  • CRMD’s FA Score: 0 green, 5 red.
According to our system of comparison, CRMD is a better buy in the long-term than BVNKF.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

CRMD’s TA Score shows that 4 TA indicator(s) are bullish.

  • CRMD’s TA Score: 4 bullish, 5 bearish.

Price Growth

BVNKF (@Biotechnology) experienced а 0.00% price change this week, while CRMD (@Biotechnology) price change was +1.14% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was +4.11%. For the same industry, the average monthly price growth was +10.01%, and the average quarterly price growth was -2.16%.

Reported Earning Dates

CRMD is expected to report earnings on Aug 07, 2025.

Industries' Descriptions

@Biotechnology (+4.11% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
BVNKF($2.14B) has a higher market cap than CRMD($894M). CRMD has higher P/E ratio than BVNKF: CRMD (52.72) vs BVNKF (10.73). CRMD YTD gains are higher at: 53.457 vs. BVNKF (1.862). BVNKF has higher annual earnings (EBITDA): 1.67B vs. CRMD (-47.32M). BVNKF has more cash in the bank: 2.18B vs. CRMD (46M). CRMD has less debt than BVNKF: CRMD (556K) vs BVNKF (128M). BVNKF has higher revenues than CRMD: BVNKF (5.72B) vs CRMD (12.3M).
BVNKFCRMDBVNKF / CRMD
Capitalization2.14B894M240%
EBITDA1.67B-47.32M-3,538%
Gain YTD1.86253.4573%
P/E Ratio10.7352.7220%
Revenue5.72B12.3M46,472%
Total Cash2.18B46M4,728%
Total Debt128M556K23,022%
FUNDAMENTALS RATINGS
BVNKF vs CRMD: Fundamental Ratings
BVNKF
CRMD
OUTLOOK RATING
1..100
5025
VALUATION
overvalued / fair valued / undervalued
1..100
48
Fair valued
78
Overvalued
PROFIT vs RISK RATING
1..100
7457
SMR RATING
1..100
7298
PRICE GROWTH RATING
1..100
4436
P/E GROWTH RATING
1..100
7842
SEASONALITY SCORE
1..100
n/a50

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

BVNKF's Valuation (48) in the null industry is in the same range as CRMD (78) in the Medical Specialties industry. This means that BVNKF’s stock grew similarly to CRMD’s over the last 12 months.

CRMD's Profit vs Risk Rating (57) in the Medical Specialties industry is in the same range as BVNKF (74) in the null industry. This means that CRMD’s stock grew similarly to BVNKF’s over the last 12 months.

BVNKF's SMR Rating (72) in the null industry is in the same range as CRMD (98) in the Medical Specialties industry. This means that BVNKF’s stock grew similarly to CRMD’s over the last 12 months.

CRMD's Price Growth Rating (36) in the Medical Specialties industry is in the same range as BVNKF (44) in the null industry. This means that CRMD’s stock grew similarly to BVNKF’s over the last 12 months.

CRMD's P/E Growth Rating (42) in the Medical Specialties industry is somewhat better than the same rating for BVNKF (78) in the null industry. This means that CRMD’s stock grew somewhat faster than BVNKF’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
CRMD
RSI
ODDS (%)
Bearish Trend 12 days ago
83%
Stochastic
ODDS (%)
Bearish Trend 12 days ago
90%
Momentum
ODDS (%)
N/A
MACD
ODDS (%)
Bearish Trend 12 days ago
87%
TrendWeek
ODDS (%)
Bearish Trend 12 days ago
87%
TrendMonth
ODDS (%)
Bullish Trend 12 days ago
78%
Advances
ODDS (%)
Bullish Trend 13 days ago
82%
Declines
ODDS (%)
Bearish Trend 18 days ago
86%
BollingerBands
ODDS (%)
Bearish Trend 12 days ago
78%
Aroon
ODDS (%)
Bullish Trend 12 days ago
77%
View a ticker or compare two or three
Interact to see
Advertisement
CRMD
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
STOCK / NAMEPrice $Chg $Chg %
AAPL200.420.21
+0.10%
Apple
SPY587.73-3.42
-0.58%
SPDR® S&P 500® ETF
BTC.X107802.330000-1192.312500
-1.09%
Bitcoin cryptocurrency
TSLA356.90-5.99
-1.65%
Tesla
GME31.21-3.80
-10.85%
GameStop Corp

BVNKF and

Correlation & Price change

A.I.dvisor tells us that BVNKF and VRAX have been poorly correlated (+27% of the time) for the last year. This A.I.-generated data suggests there is low statistical probability that BVNKF and VRAX's prices will move in lockstep.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To BVNKF
1D Price
Change %
BVNKF100%
N/A
VRAX - BVNKF
27%
Poorly correlated
-7.24%
GOVX - BVNKF
24%
Poorly correlated
-1.85%
CRMD - BVNKF
21%
Poorly correlated
-0.80%
PHGUF - BVNKF
20%
Poorly correlated
N/A
BVNRY - BVNKF
12%
Poorly correlated
-0.09%
More

CRMD and

Correlation & Price change

A.I.dvisor indicates that over the last year, CRMD has been loosely correlated with MURA. These tickers have moved in lockstep 40% of the time. This A.I.-generated data suggests there is some statistical probability that if CRMD jumps, then MURA could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To CRMD
1D Price
Change %
CRMD100%
-0.80%
MURA - CRMD
40%
Loosely correlated
-0.38%
HOTH - CRMD
30%
Poorly correlated
-1.43%
FULC - CRMD
30%
Poorly correlated
+8.66%
BTAI - CRMD
30%
Poorly correlated
-9.35%
OVID - CRMD
29%
Poorly correlated
-0.21%
More